Alternatives to Phenotips: a 2026 field guide for clinical pedigree software

Looking for an alternative to Phenotips? Here's an honest field guide. Phenotips is an established clinical platform used in 60+ countries with a strong position in phenotype-driven rare disease work — but it is not the only credible option in 2026, and it is not always the right fit. Teams search for alternatives for four common reasons: enterprise procurement friction (opaque pricing, long sales cycles), workflow mismatch (pedigree-first services that do not need an HPO-first genomic health record), a wish to use modern surfaces such as AI interpretation and programmatic APIs, and sometimes simple cost.

This page is written as a field guide, not a sales pitch. We cover four serious alternatives — TrakGene, Progeny, FamGenix, and Evagene — and we tell you honestly where each fits and where each falls short. Evagene is the platform that publishes this site, and we mark where it is weaker than the others (clinical HPO-driven diagnostics, cancer-risk model breadth against FamGenix) as plainly as we mark where it is stronger.

Short version. If HPO deep phenotyping is genuinely core to your diagnostic workflow, Phenotips remains the strongest choice and you probably should not switch — no alternative matches it on that axis today. If your workflow is pedigree-first, any of TrakGene, Progeny, FamGenix, or Evagene will feel lighter and easier to procure than Phenotips. For modern agentic workflows (AI interpretation, REST API, MCP, embeds), Evagene has the widest surface; for cancer-risk breadth (BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, QRISK3) FamGenix leads; for a modern clinician-built FHIR-aware platform, TrakGene is credible.

Why teams look for alternatives to Phenotips

The first and most cited reason is procurement. Phenotips does not publish list pricing; access is gated behind a demo and an institutional contract. For large hospitals and national services, that is normal and not an obstacle. For smaller clinics, research groups, private genetic counselling practices, and teams who need to prove a workflow before requesting a budget, a sales-led procurement cycle is often too heavy. An alternative that can be trialled on a seat in a week is sometimes not just preferable but necessary.

The second reason is workflow shape. Phenotips is built as a genomic health record, with the Human Phenotype Ontology as its organising spine and the pedigree as one component of a richer patient record. That shape fits undiagnosed rare disease clinics and phenotype-driven diagnostic services very well. It fits cancer genetics, reproductive genetics, and cascade-testing services less directly — those workflows are usually pedigree-first, with disease annotation against OMIM/ICD-10 rather than HPO features. Teams who are pedigree-first often find Phenotips's HPO-centric design brings friction they do not need. A third reason, growing in 2026, is the wish to use AI interpretation, REST APIs, and Model Context Protocol agents — surfaces Phenotips does not advertise today.

Four alternatives worth evaluating

TrakGene

TrakGene is a clinician-built clinical genetics platform with an emphasis on modern architecture and HL7 FHIR integration. Its public customer list includes NIH, NHS services, and Geisinger, which gives it credibility in both research and clinical settings. The product covers pedigree drawing, clinical documentation, and integration with laboratory information systems and electronic health records; its FHIR surface is particularly attractive to teams building against modern healthcare integration patterns.

Where TrakGene fits: clinical genetics services that want a pedigree-centred clinical platform with modern integration and a vendor who ships against clinician feedback. Where it falls short: like most enterprise players, TrakGene does not publish public pricing and does not offer a free tier, so small-team evaluation requires going through sales. HPO-driven phenotype capture is not TrakGene's headline positioning, so services whose workflow genuinely depends on HPO-first phenotype capture may still lean toward Phenotips. For teams who are pedigree-first and EHR-integration-first, TrakGene is a natural alternative.

Progeny

Progeny is among the oldest clinical pedigree vendors, with software history reaching back to 1996. Its core product is an EHR-native clinical genetics suite covering pedigree drawing, clinical documentation, risk modelling, and research cohort management. Its installed base in large institutions gives it proven longevity, and for services already running Progeny, migration friction is usually a strong reason to stay.

Where Progeny fits: institutions that want a pedigree platform with decades of clinical footprint and that value vendor longevity. Where it falls short: third-party reports in recent years repeatedly cite rising pricing and an architectural heritage that predates modern cloud patterns. Independent reviewers frame Progeny as a capable but increasingly expensive product that asks a higher premium than newer peers. As with Phenotips and TrakGene, public pricing is not published. For teams looking for a modern, API-first, AI-aware alternative to Phenotips, Progeny is unlikely to be that alternative — it shares many of Phenotips's enterprise characteristics, including opaque pricing, without Phenotips's HPO depth.

FamGenix

FamGenix is a clinical genetics platform with a distinctive emphasis on cancer risk breadth. It runs BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, and QRISK3 simultaneously from a single pedigree — a combination that is genuinely hard to match in the category. It is used in clinical genetics and primary care screening settings, offers a free Individual tier, and publishes tiered pricing, which makes evaluation materially easier than with sales-led vendors.

Where FamGenix fits: services whose core work is hereditary cancer risk assessment, particularly breast, ovarian, and prostate risk, and services that want a product with the broadest simultaneous coverage of cancer risk models. Its free Individual tier makes it attractive for practitioners who want to evaluate without procurement overhead. Where it falls short relative to Phenotips: FamGenix is not positioned as a genomic health record and does not advertise HPO deep phenotyping. AI interpretation, REST APIs, MCP servers, and agentic integration are not FamGenix's focus, so teams pursuing modern workflow automation will find it less extensible than Evagene. For cancer risk specifically, however, few products match its breadth.

Evagene

Evagene is a browser-first, pedigree management platform for clinical genetics, research, and family history. Its feature set covers gesture-driven pedigree drawing with NSGC/ISCN standard notation, a 230+ disease catalogue cross-referenced to five ontology systems — ICD-10, OMIM, MONDO, Orphanet, and Disease Ontology (DOID), searchable by CURIE — cancer family-history models including Gail/BCRAT and an IBIS-style Tyrer-Cuzick approximation (a research/teaching approximation of the published Tyrer/Duffy/Cuzick 2004 algorithm, not the official IBIS binary) plus Claus, Couch, Frank, Manchester, NICE, Amsterdam II and revised Bethesda, the BayesMendel BRCAPRO/MMRpro/PancPRO models and an educational prostate-cancer model, Mendelian inheritance calculators for autosomal dominant, autosomal recessive, and X-linked recessive conditions, a karyogram viewer, and automatic consanguinity detection using Wright's coefficient. In 2026 it added educational HPO phenotyping: you can browse and search a curated Human Phenotype Ontology catalogue and attach observed or excluded HPO features to individuals with onset and severity. From an individual's recorded HPO features the platform surfaces candidate associated genes as educational reference associations — candidate associations only, never a ranked likelihood, nothing asserted about a person, and no diagnosis or recommendation (the same reference-data framing as Related Concepts).

Where Evagene is distinctive is the modern surface layer. AI-assisted draft summaries for educational / research review use bring-your-own-key (BYOK) LLMs for Anthropic Claude and OpenAI GPT, which means your service uses its own LLM account — text goes directly to the provider you have already risk-assessed, not through a vendor-hosted model. Analysis Templates let you codify a house style for AI-drafted summaries. The catalogue exposes 21 built-in published risk-model algorithms (illustrative and for teaching, including a new educational prostate-cancer family-history model that references external guidelines only), and the Related Concepts educational correlation graph surfaces 1,100+ curated associations as reference data (not risk analysis). A gated relatedness / IBD analysis module computes pairwise kinship coefficients, per-individual inbreeding, Jacquard condensed-identity / expected genome-wide IBD sharing (k0/k1/k2), and a gene-dropping relatedness simulation for educational and research use. A scoped, rate-limited REST API, HMAC-SHA256-signed webhooks, an MCP server exposing 27 tools to AI agents such as Claude Desktop and Claude Code, the "Evagene Pedigree Builder" ChatGPT Custom GPT (natural-language family history to pedigree), a guided Family History Questionnaire (intake to pedigree), GA4GH Phenopackets v2 import and export alongside GEDCOM 5.5.1 and CanRisk/BOADICEA export, and an embeddable pedigree viewer (iframe/SVG/JS) make Evagene an unusually programmable pedigree-modelling tool.

Where Evagene falls short: its HPO phenotyping and phenotype-to-gene associations are educational documentation and reference data, not the clinical phenotype-driven diagnostic surface Phenotips provides — if HPO-driven clinical diagnostics is central, Phenotips remains stronger. Its cancer-risk coverage is meaningful — Gail/BCRAT, an IBIS-style Tyrer-Cuzick approximation, Claus and the BayesMendel BRCAPRO/MMRpro/PancPRO models among 21 illustrative algorithms — but it does not bundle BOADICEA (it exports a ##CanRisk 2.0 file to canrisk.org instead), its Tyrer-Cuzick is an approximation rather than the official IBIS binary, and it lacks QRISK3, so FamGenix's official bundled BOADICEA v6 / Tyrer-Cuzick v8 / Gail / Claus / QRISK3 set remains broader for a cancer-dominated practice. Evagene is currently in Alpha; procurement controls appropriate to large hospitals (formal certification, SLAs, dedicated compliance contracts) should be confirmed at contract time. Alpha access is free via the Evagene waiting list.

Feature comparison matrix

The matrix summarises publicly advertised features across Phenotips and the four alternatives. A tick means the feature is publicly documented. A dash means it is not publicly advertised, which does not necessarily mean it is absent — enterprise vendors often keep detailed capability lists behind sales. Where nuance matters we add a short note.

Compiled from publicly available product pages and documentation as of June 2026. "—" means not publicly advertised; it does not necessarily mean the capability is absent.

How to choose

The decision usually turns on workflow shape rather than feature count. Four profiles:

HPO-first rare disease diagnostics. If your diagnostic process genuinely starts from HPO phenotype capture and uses automated gene suggestion to drive clinical decisions, stay with Phenotips or consider PedigreeTool (with its explicit non-clinical disclaimer in mind). Evagene added educational HPO phenotyping and phenotype-to-gene educational associations in 2026, which closes the documentation gap for teaching and research, but those outputs are reference data — not the clinical phenotype-driven diagnostic surface Phenotips provides.

Hereditary cancer risk at scale. If your clinic's volume is dominated by breast/ovarian/prostate risk assessment, FamGenix's official BOADICEA v6 + Tyrer-Cuzick v8 + Gail + Claus + QRISK3 combination is hard to beat. Evagene is credible and covers a broader monogenic surface — Gail/BCRAT, an IBIS-style Tyrer-Cuzick approximation and the BayesMendel models among them — but it exports a CanRisk file for BOADICEA rather than bundling it, its Tyrer-Cuzick is an approximation rather than the official binary, and it has no QRISK3.

Modern clinical genetics with FHIR/EHR integration. TrakGene's clinician-built FHIR-aware architecture is the strongest fit. Evagene's REST API and webhook surface covers similar needs for teams who prefer to build their own integration layer.

Pedigree-first workflow with AI and programmatic access. Evagene is the intended fit — BYOK LLM, MCP server (27 tools), Analysis Templates, scoped REST API, embeddable viewer, educational HPO phenotyping, and GEDCOM / 23andMe / GA4GH Phenopackets v2 import-export. Start on Alpha, evaluate on a real case, and progress to contract if it fits. A deeper comparison is available in our Phenotips vs Evagene article.

Frequently asked questions

Further reading

• Phenotips vs Evagene: a detailed comparison
• Clinical genetics pedigree tools: a field guide
• Hereditary cancer risk assessment
• Pedigree drawing software
• GEDCOM pedigree software
• Mendelian inheritance calculator
• The Evagene platform layer (API, MCP, webhooks)